- Millennium has expanded the VELCADE Patient Assistance Program for all patients from areas affected by Hurricane Katrina, to ensure that every patient who needs VELCADE is able to receive it. This will ensure that ongoing therapy is not interrupted, and that any newly diagnosed patients can be treated without hesitation. If you are a patient from the affected area, call 1-866-VELCADE and speak to a reimbursement specialist. You will need to provide your home address in the hurricane stricken area, the name of the physician or clinic where you were receiving care, your current contact information, and the name and contact information for the physician who is currently treating you.
- The International Myeloma Foundation Noted in Wall Street Journal
The IMF was listed in the September 7th edition of the Wall Street Journal as one of six top advocacy organizations offering help and preparedness advice for patients affected by Hurricane Katrina and those concerned about a future natural disaster or other emergency. The article entitled, "A Medical Checklist" can be found on pages D1 and D5 of the 9/7/05 WSJ.
- IMF Patient Handbook translated into Hebrew
This translation was one of the first projects undertaken by AMEN - The Israeli Association of Myeloma Patients. Another was the first meeting of the Israeli Myeloma Working Group. Our thanks to them for this much-needed resource.
- Eliminating Suffering and Death Due to Cancer by 2015: The Future of Cancer Research
The National Cancer Institute's Office of Liaison Activities is pleased to offer a teleconference series on crosscutting issues in cancer research. Members of cancer advocacy organizations, survivors, family, and friends are encouraged to participate in each call to learn more about NCI's important cancer research programs and how advocates are involved. Callers will have the opportunity to ask questions of panel members. The first call will be held Monday, September 19th, at 1pm (EDT), call in number is 1-888-889-1957, passcode 2015#.
- Exiled from Their Lousiana Labs, Scientists Assess Their Losses
Hurricane Katrina has devastated scientific research in New Orleans, claiming thousands of laboratory animals, ruining valuable caches of tissue, and interrupting clinical experiments as patients scattered across the nation. Restoring what has been lost could easily take years, researchers said. (from Boston.com)
- Trial with AMD-3100 shows new drug may help cancer patients who need stem cell transplants
Researchers were attempting to determine if patients with multiple myeloma or non-Hodgkin's lymphoma who received the drug AMD-3100 along with the standard drug G-CSF (granulocyte-colony stimulating factor) would have more stem cells available for transplantation. of the 25 patients (10 patients with multiple myeloma and 15 patients with non-Hodgkin's lymphoma) given the drug combination could move enough cells from the marrow to the bloodstream compared to only 64 percent of those who had G-CSF alone. (from EurekAlert)
- ImmunoGen, Inc. Initiates Clinical Testing of HuN901-DM1 for Treatment of Multiple Myeloma; Study Expands HuN901-DM1 Clinical Development Program
The huN901-DM1 multiple myeloma study is being conducted at the Jerome Lipper Center for Multiple Myeloma of the Dana-Farber Cancer Institute in Boston, MA. Robert Schlossman, MD, is the Principal Investigator. Co-investigators in the study include Kenneth Anderson, MD, Paul Richardson, MD, and Nikhil Munshi, MD, of the Jerome Lipper Center. Additional clinical centers are expected to be added.(from Business Wire)
- Mayo Clinic Research Shows Promise For Myeloma Patients Using A New Combination Of Drugs
"Previous studies have shown Rev/Dex to be effective for recurrent or highly resistant forms of myeloma," says S. Vincent Rajkumar, M.D., Mayo Clinic hematological oncologist and lead investigator of the study, "In this study, the first one to use the combination as initial therapy in newly diagnosed patients, we find that the Rev/Dex combination reduced the myeloma cancer protein levels by more than half in 91 percent of patients -- much higher than response rates obtained with current approved therapies." (from Science Daily)
- Targeted "smart drugs" may change pharmaceutical industry
Use of genetic tests to yield better diagnoses and target prescription drugs for specific populations may mean massive changes for a pharmaceutical industry that seeks to develop treatments for millions of people. (Note: Although this article is not about myeloma, the concept of using genetics to target treatment is the basis of Bank On A Cure®.) (from Business Week)
WHAT'S NEW IN RESEARCH
CLINICAL TRIAL OF THE WEEK
As part of our ongoing focus on myeloma research, the Myeloma Minute will spotlight a clinical trial of interest each week. This week, we are looking at using lenalidomide in treating patients who are undergoing autologous stem cell transplant.
Phase III Randomized Study of Lenalidomide (Revlimid) as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving lenalidomide after autologous stem cell transplant may kill any remaining cancer cells. It is not yet known whether lenalidomide is more effective than a placebo when given after autologous stem cell transplant in treating multiple myeloma. This randomized phase III trial is studying lenalidomide to see how well it works compared to a placebo in treating patients who are undergoing autologous stem cell transplant for multiple myeloma.
- Dysfunctional T regulatory cells in multiple myeloma
Prabhala R, et al
Blood published 8 September 2005, 10.1182/blood-2005-08-3101
- The paradox of response and survival in cancer therapeutics
Carol A Huff, William Matsui, B D Smith, and Richard J Jones
Blood published 8 September 2005, 10.1182/blood-2005-06-2517
- Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
Moreau P, et al
Blood published 6 September 2005, 10.1182/blood-2005-06-2573
- CD8+ T cells specific for cancer-germline gene antigens are found in many patients with multiple myeloma and their frequency correlates with disease burden
Goodyear O, et al
Blood published 6 September 2005, 10.1182/blood-2005-02-0563
- CLINICAL TRIALS
If you would like more information on the CNTO 328 or any other clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
UPCOMING SEMINARS AND CLINICAL
Patient & Family Seminar - September 24, 2005|
Patient & Family Seminar - October 7, 2005|
Patient & Family Seminar - October 10, 2005|
Patient and Family Seminar - October 22, 2005|
Patient and Family Seminar - October 28, 2005|
Symposium - November 5, 2005|
with the Arizona Myeloma Network
UPCOMING EVENTS AND EXCITING
The IMF's comprehensive "How-to-FUNdraise"
guide is what you need if you're thinking about fundraising in your
community, but don't know where to start. The guide will give you the "A
to Z" of fundraising ideas, and other helpful
See complete list of 2005 UPCOMING
SHOP FOR THE IMF
Shop at leading internet retailers (e-tailers) like Amazon.com, and they will donate a portion of your
purchase to the IMF. To do this, you access their site via special URLs we
have set up. For Amazon, it's http://amazon.myeloma.org instead of amazon.com. It will
take you to the same place, but any purchase you make during that visit
will be credited to the IMF.
Here is a hot title you may be interested in:
|Our own Rosanne Kalick, who co-leads the Westchester, NY support group, has written a book titled "Cancer Etiquette: What to do, what to say, when someone you love has cancer." You can order now at a discount.
"The more I investigated, the more convinced I became that most people do not know what to say or what to do when someone they know or love has cancer. This book will help them find words that will not offend or hurt, but will help to comfort. This book will enable them to perform simple acts of loving-kindness that are blessings to the patient."
Visit our Shop for
the IMF page at http://shop.myeloma.org for express links to other
popular etailers who will donate a portion of your purchase to the
New! Multiple Colors for Multiple Myeloma Keychains and Earrings
The gift-giving holidays will be upon us sooner than we think. And there are always birthdays, anniversaries, and "just because you're you" occasions. Here are two new items to help support the International Myeloma Foundation: colorful keychains and chandelier earrings of Swarovski crystals.
Imagine Moving Forward is the theme of the IMF's popular myeloma bracelet. At medical
conferences and patient & family seminars we see people wearing them
in honor, celebration, or in memory of a loved one. They're only $1 each
in sets of 10, so order them for everyone you know who has been touched by
myeloma. Order them on the web. If you have questions about the
bracelets or would like more information, contact Suzanne Battaglia at
(800) 452-2873, ext. 227, or SBattaglia@myeloma.org.
Multiple Myeloma Awareness
The response has been great for the new garnet bracelet
IMFer Kristi Difford has added to her line of beautiful custom bracelets
to honor those who have joined the struggle against multiple myeloma.
See more exciting ways to help the IMF continue its
important work in education, support and
- More Options, More Hope
Scientific Advisor Dr. Paul Richardson of the Dana-Farber Cancer
Institute on early use of Velcade.
The HealthWell Foundation has recently opened the
Multiple Myeloma fund to help even more patients gain access to the best
health care available. You can contact them at (800) 675-8416 or
Access Network Foundation (PANF) provides copay assistance for
myeloma. Thalomid is the MRDD product covered for this condition. The
PANF formerly just covered qualified myeloma patients_ erythropoietin
alpha expenses. Patients or healthcare providers may initiate the
application process. Applications must be completed by both physician
and patient, and income verification is required. Their phone number is
|Help Us Help Others...|
As a non-profit organization, the
IMF is completely dependent on the support of our members. Tax-deductible
donations in honor of a friend or family member make great gifts and are a
wonderful way to celebrate a special occasion. You can donate
online or by calling the IMF at (800) 452-CURE. We sincerely thank you
for your support.